Quick Answer
Silence Therapeutics plc reported Operating Income Loss of -$91.08 million for the year ending 2025.
- Silence Therapeutics plc showed a decrease of -43.8% in Operating Income Loss from 2024 to 2025.
- This data is from Silence Therapeutics plc's annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: -$5.58 million | Q2 2024: -$23.39 million | Q3 2024: -$30.00 million | Q1 2025: -$28.41 million | Q2 2025: -$23.96 million | Q3 2025: -$26.24 million.
- Over the full 4 years of available data (2022 to 2025), Silence Therapeutics plc's Operating Income Loss has declined by 49.2%.
- Historical annual values: Fiscal year 2025: -$91.08 million | Fiscal year 2024: -$63.32 million | Fiscal year 2023: -$64.38 million | Fiscal year 2022: -$61.04 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: